Skip to main content
MyPeptideMatch logoMyPeptideMatch
Reviewed by MyPeptideMatch Editorial TeamLast reviewed February 2026Updated February 2026

Kisspeptin Dosing Protocol: 10 mg Vial — HPG Axis & Sexual Function Guide

Kisspeptin-10 dosing protocol for subcutaneous injection — targeting HPG axis reactivation, LH pulse restoration, and sexual arousal enhancement.

Quickstart highlights

Kisspeptin (encoded by KISS1 gene) is a family of hypothalamic neuropeptides that bind the GPR54 receptor on GnRH neurons, serving as the master regulator of the HPG axis.

  • Concentration: 2 mg/mL (10 mg vial + 5 mL bacteriostatic water).
  • At 2 mg/mL: 500 µg = 25 units, 1 mg = 50 units per injection.
  • Every-other-day dosing is essential — daily kisspeptin causes GPR54 desensitization and HPG suppression.
  • Jayasena et al. 2014: pulsatile kisspeptin-10 restored LH pulsatility in 10/14 hypothalamic amenorrhea patients.
  • One 10 mg vial provides 10 doses at 1 mg or 20 doses at 500 µg.

Dosing table

For educational reference only. Your prescribing provider may adjust doses based on your clinical profile and response.

WeekDose (µg)UnitsFrequencyNotes
1-450025Every other day500 µg — 25 units; pulsatile stimulation of HPG axis; 10 mg vial provides 20 doses
5-12100050Every other day1 mg — 50 units; increased LH pulsatility; 10 mg vial provides 10 doses

Reconstitution steps

  1. Draw 5 mL bacteriostatic water (two 2.5 mL draws); inject slowly down the vial wall.
  2. Swirl gently until powder dissolves; do not shake.
  3. Final concentration: 2 mg/mL. At 2 mg/mL: 500 µg = 25 units, 1 mg = 50 units.
  4. Label with date; refrigerate at 2–8 °C. Use within 28 days.

Supplies needed

8-week plan

  • 2 vials
  • 28 syringes
  • 10 mL bac water
  • 28 alcohol swabs
Need clinics? See vetted providers →

Protocol overview & cycle notes

Restore physiological HPG axis pulsatility and enhance sexual arousal through every-other-day kisspeptin-10 subcutaneous injections targeting hypothalamic KNDy neurons and GnRH release.

Cycle length: 12 weeks on.

Off-cycle: 6–8 weeks off; monitor LH/FSH and testosterone/estradiol during off-cycle.

Storage & handling

Lyophilized: store below 25 °C. Reconstituted at 2 mg/mL: refrigerate 2–8 °C; use within 28 days.

Injection & tracking tips

  • Inject subcutaneously every other day at the same time (morning or evening) to maintain pulsatile HPG stimulation without receptor desensitization.
  • Daily injection of kisspeptin causes receptor downregulation and paradoxical HPG suppression — every-other-day spacing is essential.
  • Kisspeptin effects on libido and arousal are often reported within 2–4 weeks; hormonal changes (LH, testosterone) measurable at 4–6 weeks.

Tracking

Logging helps you and your provider spot patterns and adjust dose or timing.

  • Measure serum LH, FSH, testosterone (men) or estradiol/progesterone (women) at baseline and every 4 weeks.
  • Track libido intensity and sexual satisfaction (0–10 subjective scale) weekly.
  • Monitor for menstrual cycle changes in women — kisspeptin can restore or alter ovulatory patterns.
Log your cycle in the calculator →

How this works & references

Kisspeptin (encoded by KISS1 gene) is a family of hypothalamic neuropeptides that bind the GPR54 receptor on GnRH neurons, serving as the master regulator of the HPG axis. Kisspeptin-10 is the 10-amino acid active core sequence. Pulsatile kisspeptin administration restores LH pulsatility in hypogonadal men and hypothalamic amenorrhea patients. Jayasena et al. (2014) demonstrated that kisspeptin-10 (0.4 nmol/kg, approximately 1.6 µg/kg, IV) restored LH pulse frequency in 10 of 14 hypothalamic amenorrhea patients. Sexual arousal effects are mediated through olfactory and limbic kisspeptin receptors independently of LH.

Sources

Frequently asked questions

Can kisspeptin help restore testosterone after TRT?
Potentially — kisspeptin stimulates GnRH → LH → Leydig cell testosterone production. In men with TRT-suppressed HPG axis, pulsatile kisspeptin combined with gradual TRT reduction may help reactivate endogenous testosterone production. This approach is experimental and requires careful monitoring of LH, FSH, and testosterone every 4 weeks.
Why is every-other-day dosing important?
Continuous kisspeptin stimulation causes GPR54 receptor internalization and downregulation — paradoxically suppressing GnRH and LH (similar to leuprolide's mechanism). Pulsatile stimulation (every other day or less frequently) maintains receptor sensitivity. This is the same principle as pulsatile GnRH therapy for hypogonadotropic hypogonadism.
Is kisspeptin effective for sexual desire in both men and women?
Clinical studies show kisspeptin enhances sexual arousal in both sexes. Dhillo et al. and Rastrelli et al. demonstrated libido-enhancing effects independent of LH/testosterone changes, suggesting direct central (limbic/olfactory) kisspeptin receptor effects on sexual motivation beyond HPG stimulation.
Can kisspeptin help with hypothalamic amenorrhea?
Yes — Jayasena et al. (2014) is the landmark study: pulsatile IV kisspeptin-10 restored LH pulsatility in 71% of hypothalamic amenorrhea patients. Subcutaneous administration at higher doses (500 µg–1 mg) every other day is the compounding protocol extrapolation, though IV studies use weight-based dosing at much lower absolute µg amounts.
Is kisspeptin FDA-approved?
No — kisspeptin is in clinical development but not FDA-approved as of February 2026. It is being studied for hypothalamic amenorrhea, male hypogonadotropic hypogonadism, and fertility induction. Compounded kisspeptin-10 is available for research protocols under physician supervision.

Related protocols

This content is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting any peptide therapy. Dosing and protocols may vary by formulation and prescriber.